ESA
Erythropoiesis-Stimulating Agents (ESAs) are a type of medication used to treat certain types of anemia, particularly the anemia associated with chronic kidney disease (CKD), cancer chemotherapy, and HIV/AIDS treatment. ESAs work by stimulating the bone marrow to produce more red blood cells, thereby increasing the oxygen-carrying capacity of the blood.
Mechanism of Action[edit | edit source]
ESAs mimic the action of erythropoietin, a hormone naturally produced by the kidneys that plays a key role in the production of red blood cells. In conditions such as chronic kidney disease, the kidneys' ability to produce adequate amounts of erythropoietin may be compromised, leading to a decrease in red blood cell production and, consequently, anemia. By administering ESAs, the erythropoietin levels in the body are increased, thereby stimulating the bone marrow to produce more red blood cells.
Indications[edit | edit source]
ESAs are primarily indicated for the treatment of anemia associated with:
- Chronic kidney disease (CKD)
- Cancer chemotherapy
- HIV/AIDS treatment
- Other conditions as determined by a healthcare provider
Risks and Considerations[edit | edit source]
While ESAs are effective in treating anemia, their use must be carefully monitored due to potential risks and side effects. These may include:
- Increased risk of thrombosis (blood clots)
- Elevated blood pressure
- Risk of stroke
- Potential for tumor progression in patients with certain types of cancer
It is crucial for patients receiving ESAs to have their hemoglobin levels regularly monitored to avoid complications associated with overcorrection of anemia.
Types of ESAs[edit | edit source]
Several types of erythropoiesis-stimulating agents are available, including:
- Epoetin alfa (Epogen, Procrit)
- Darbepoetin alfa (Aranesp)
- Methoxy polyethylene glycol-epoetin beta (Mircera)
Each ESA has its own dosing schedule and method of administration, which may include intravenous (IV) or subcutaneous (SC) injections.
Conclusion[edit | edit source]
Erythropoiesis-stimulating agents represent a significant advancement in the treatment of anemia associated with chronic diseases. However, their use requires careful consideration of the potential risks and benefits, as well as close monitoring by healthcare professionals.
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
